Risk factors of adverse drug reaction caused by nimesulide in Shanghai patients with osteoarthropathy.

W Shi, Y M Wang, S L Li, M Yan, B Y Chen, N N Chen, D Li
{"title":"Risk factors of adverse drug reaction caused by nimesulide in Shanghai patients with osteoarthropathy.","authors":"W Shi,&nbsp;Y M Wang,&nbsp;S L Li,&nbsp;M Yan,&nbsp;B Y Chen,&nbsp;N N Chen,&nbsp;D Li","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The aim of this study was to investigate the risk factors for adverse drug reactions (ADRs) to nimesulide in patients from Shanghai with osteoarthropathy. A retrospective epidemiological study was performed to obtain information (observational variables) on demographics, primary disease, family history of disease, quality of life, dietary habits, lifestyle, use of nonsteroidal anti-inflammatory drugs (NSAIDs) and ADR history of NSAIDs. Univariate and multivariate analyses were performed to establish the relationship between these observational variables and the occurrence of ADRs caused by nimesulide. Among the 726 variables, five risk factors for ADRs to nimesulide were identified. The study showed an increased risk for ADR occurrence with increased scoring of the following four factors: (i) \"Concomitant drug therapy\" (odds ratio [OR]: 4.66, 95% confidence intervals [CI]: 1.26-17.26, p < 0.05); (ii) \"Compared with six months ago, how would you rate your health in general now?\" (OR: 1.38, 95% CI: 1.03-1.84, p < 0.05); (iii) \"General feeling of health status\" (OR: 1.27, 95% CI: 1.03-1.56, p < 0.05) and (iv) \"1 expect my health to get worse\" (OR: 2.05, 95% CI: 1.22-3.44, p < 0.01). There was a decreased risk for ADR occurrence with increased scoring of the factor \"Have you ever suffered from depression that impacted on your life?\" (OR: 0.15, 95% CI: 0.03-0.66, p < 0.05). The predictive model for the overall incidence rate of ADRs caused by nimesulide was then established. In conclusion, the predictive model helps to indicate the risk of ADRs to nimesulide and provides clinicians with an alternative method for decision making when prescribing this drug.</p>","PeriodicalId":11336,"journal":{"name":"Drugs under experimental and clinical research","volume":"29 4","pages":"161-8"},"PeriodicalIF":0.0000,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs under experimental and clinical research","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The aim of this study was to investigate the risk factors for adverse drug reactions (ADRs) to nimesulide in patients from Shanghai with osteoarthropathy. A retrospective epidemiological study was performed to obtain information (observational variables) on demographics, primary disease, family history of disease, quality of life, dietary habits, lifestyle, use of nonsteroidal anti-inflammatory drugs (NSAIDs) and ADR history of NSAIDs. Univariate and multivariate analyses were performed to establish the relationship between these observational variables and the occurrence of ADRs caused by nimesulide. Among the 726 variables, five risk factors for ADRs to nimesulide were identified. The study showed an increased risk for ADR occurrence with increased scoring of the following four factors: (i) "Concomitant drug therapy" (odds ratio [OR]: 4.66, 95% confidence intervals [CI]: 1.26-17.26, p < 0.05); (ii) "Compared with six months ago, how would you rate your health in general now?" (OR: 1.38, 95% CI: 1.03-1.84, p < 0.05); (iii) "General feeling of health status" (OR: 1.27, 95% CI: 1.03-1.56, p < 0.05) and (iv) "1 expect my health to get worse" (OR: 2.05, 95% CI: 1.22-3.44, p < 0.01). There was a decreased risk for ADR occurrence with increased scoring of the factor "Have you ever suffered from depression that impacted on your life?" (OR: 0.15, 95% CI: 0.03-0.66, p < 0.05). The predictive model for the overall incidence rate of ADRs caused by nimesulide was then established. In conclusion, the predictive model helps to indicate the risk of ADRs to nimesulide and provides clinicians with an alternative method for decision making when prescribing this drug.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
上海地区骨关节病患者尼美舒利药物不良反应危险因素分析。
本研究旨在探讨上海地区骨关节病患者尼美舒利药物不良反应(adr)的危险因素。回顾性流行病学研究获取人口统计学、原发疾病、家族史、生活质量、饮食习惯、生活方式、非甾体类抗炎药(NSAIDs)使用情况和非甾体类抗炎药不良反应史等信息(观察变量)。进行单因素和多因素分析,以建立这些观察变量与尼美舒利引起的不良反应发生之间的关系。在726个变量中,确定了尼美舒利不良反应的5个危险因素。研究显示,以下四个因素得分越高,发生不良反应的风险越高:(i)“联合药物治疗”(优势比[OR]: 4.66, 95%可信区间[CI]: 1.26-17.26, p < 0.05);(2)“与六个月前相比,你如何评价你现在的总体健康状况?”(OR: 1.38, 95% CI: 1.03 ~ 1.84, p < 0.05);(3)“总体健康状况感觉”(OR: 1.27, 95% CI: 1.03-1.56, p < 0.05)和(iv)“我预计我的健康状况会变差”(OR: 2.05, 95% CI: 1.22-3.44, p < 0.01)。“你是否曾患过影响你生活的抑郁症?”这一因素得分越高,发生不良反应的风险就越低。(OR: 0.15, 95% CI: 0.03 ~ 0.66, p < 0.05)。建立尼美舒利不良反应总发生率的预测模型。总之,该预测模型有助于表明尼美舒利的不良反应风险,并为临床医生在处方该药时提供了另一种决策方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Oral acute and subchronic toxicity of D-004, a lipid extract from Roystonea regia fruits, in rats. Evaluation of carnitine, acetylcarnitine and isovalerylcarnitine on immune function and apoptosis. Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteers. Molecular mechanisms for vascular injury in the metabolic syndrome. Quercus suber cork extract displays a tensor and smoothing effect on human skin: an in vivo study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1